Stay updated on BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.

Latest updates to the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.0%

- Check69 days agoChange DetectedThe page shows a new revision label, 'v3.4.2', replacing 'v3.4.1'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check76 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this is a minor metadata page change and does not affect study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check98 days agoChange DetectedVersion updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.0%

- Check120 days agoChange DetectedThe page now lists study locations by state (Arkansas, California, Florida, Kentucky, Louisiana, Missouri, Nevada, New Jersey, Ohio, South Carolina, Texas) and shows an updated revision tag (v3.3.3). The HHS Vulnerability Disclosure link was removed.SummaryDifference1%

Stay in the know with updates to BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.